other material
confidence high
sentiment neutral
materiality 0.50
Eterna Therapeutics enters exclusive license with Factor Bioscience for cancer, autoimmune, rare disease tech
Ernexa Therapeutics Inc.
- Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.
- Pays Factor $208,333/month for first 12 months and $50,000/month for first 9 months for patent costs.
- Initial term one year, auto-renews; Eterna may terminate for any reason with 90 days notice.
- Factor to provide services and materials to facilitate development and scale-up at third-party facilities.